OBP 801

Drug Profile

OBP 801

Alternative Names: OBP-801; YM 753

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Kyoto Prefectural University of Medicine; Oncolys BioPharma
  • Class Antineoplastics; Cyclic peptides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Glaucoma
  • Discontinued Haematological malignancies

Most Recent Events

  • 11 Jul 2018 Phase-I development in Solid tumours is ongoing in USA (IV) (Oncolys BioPharma pipeline, July 2018)
  • 11 Jul 2018 Preclinical trials in Glaucoma in Japan (Ophthalmic) (Oncolys BioPharma pipeline, July 2018)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top